Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.

Saved in:
Bibliographic Details
Title: Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.
Authors: Atanasova, Elena1 (AUTHOR), Milosevic, Dragana2 (AUTHOR), Bornschlegl, Svetlana1 (AUTHOR), Krucker, Karen P.3 (AUTHOR), Jacob, Eapen K.4 (AUTHOR), Carmona Porquera, Eva M.5 (AUTHOR), Anderson, Dagny K.5 (AUTHOR), Egan, Ashley M.5 (AUTHOR), Limper, Andrew H.5 (AUTHOR), Dietz, Allan B.1,3 (AUTHOR) Dietz.allan@mayo.edu
Source: Stem Cell Research & Therapy. 1/31/2022, Vol. 13 Issue 1, p1-16. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17576512
DOI:10.1186/s13287-021-02692-0